Kymera Therapeutics (NASDAQ:KYMR) Research Coverage Started at Citigroup
Citigroup began coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $52.00 target price on the stock. KYMR has been the subject of a number of other research reports. BTIG Research began coverage on shares of […]
